What is Leerink Partnrs’ Forecast for TENX FY2029 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for shares of Tenax Therapeutics in a report issued on Tuesday, February 4th. Leerink Partnrs analyst D. Risinger expects that the specialty pharmaceutical company will post earnings per share of $0.63 for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share.

Several other equities analysts have also recently issued reports on the stock. Guggenheim assumed coverage on shares of Tenax Therapeutics in a research note on Monday, October 14th. They set a “buy” rating and a $16.00 target price on the stock. Leerink Partners began coverage on shares of Tenax Therapeutics in a report on Thursday, October 24th. They issued an “outperform” rating and a $16.00 target price on the stock. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $16.00.

Tenax Therapeutics Stock Up 6.3 %

Shares of NASDAQ:TENX opened at $7.07 on Wednesday. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $17.00. The stock’s fifty day moving average price is $6.12 and its 200-day moving average price is $4.74.

Institutional Investors Weigh In On Tenax Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in TENX. Vestal Point Capital LP purchased a new position in shares of Tenax Therapeutics in the third quarter worth approximately $288,000. Stonepine Capital Management LLC bought a new position in Tenax Therapeutics in the third quarter worth approximately $173,000. Finally, Sphera Funds Management LTD. purchased a new position in shares of Tenax Therapeutics during the 3rd quarter worth $101,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.